3 High-Growth Small-Cap Stocks to Buy Right Now

Given their excellent growth prospects, these three small-cap stocks can deliver superior returns over the next three years.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Small-cap stocks have high-growth potential and could deliver superior returns in the long run. However, these stocks are highly susceptible to market volatilities and are riskier. So, investors with higher risk-tolerance capacity can buy the following three stocks to earn superior returns over the next three years.

Aurora Cannabis

Despite the continued weakness in the cannabis space, I have picked Aurora Cannabis (TSX:ACB)(NYSE:ACB) as my first pick due to the expanding cannabis market due to its growing medical usages and increased legalization. The company had also posted an improved fourth-quarter performance last month, with its adjusted EBITDA losses and cash burn falling year over year.

Meanwhile, Aurora Cannabis has acquired around 20% of the Canadian medical cannabis market while enjoying a higher gross margin of 60%. So, the company is planning to allocate more resources to the segment to increase its market share further. It is also expanding its presence in the international market through new product launches, innovation, and strengthening its supply chain.

Additionally, Aurora Cannabis has planned to launch higher-THC content premium products in the recreational cannabis space to boost its sales and margins. Meanwhile, the company has also taken several cost-reducing initiatives, which can deliver $60-$80 million of savings over the next 18 months. So, given its healthy growth prospects and cheaper valuation, I am bullish on Aurora Cannabis.

Savaria

With returns of around 39% this year, Savaria (TSX:SIS) has outperformed the broader equity markets. Its strong performance in the first six months and the acquisition of Handicare appear to have driven its stock price higher. Despite the steep rise, the mobility and accessibility solutions provider still trades at an attractive forward price-to-sales multiple of 1.8.

Meanwhile, the demand for Savaria’s products and solutions could increase in the coming years amid the growing aging population and rising income levels. Besides, the acquisition of Handicare has added new production facilities, expanded its product offering, increased its geographical presence, provided cross-selling opportunities, and diversified its revenue stream.

Further, Savaria’s management had raised its monthly dividends by 4.17% to $0.0417 per share, with its forward yield standing at 2.49%. So, given its healthy growth prospects, attractive valuation, and steady monthly dividends, I am bullish on Savaria. Analysts also look bullish on Savaria, with all the eight analysts issuing a buy rating.

Cineplex

Although Cineplex (TSX:CGX) has witnessed a strong buying this year, it is still trading at a significant discount from its pre-pandemic levels, providing an excellent buying opportunity. With the easing of restrictions, the company has reopened all its screens from July 17. Its subscription programs, enhanced safety measures, and growing food delivery services could boost its financials in the coming quarters. Also, the company could benefit from the widespread vaccination, pent-up demand, and new movie releases.

Additionally, Cineplex has taken several cost-reduction measures and strengthened its liquidity positions, which could help it bounce back quickly. Meanwhile, it is also trading at an attractive valuation, with its forward price-to-sales multiple standing at 0.6. So, given the improving business environment and its cheap valuation, I expect Cineplex to deliver superior returns over the next three years. Meanwhile, analysts favour a hold rating, with four of the seven analysts issuing a “hold” rating.

Should you invest $1,000 in NorthWest Healthcare Properties right now?

Before you buy stock in NorthWest Healthcare Properties, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and NorthWest Healthcare Properties wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends CINEPLEX INC. and Savaria Corp. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »